uniQure N.V.: management transactions · United States · SEC (Form 4)

About uniQure N.V.

uniQure N.V. is a gene-therapy biotechnology company listed on the U.S. NASDAQ exchange under the ticker QURE and headquartered across the United States and Europe, with key operations in Amsterdam and Lexington, Massachusetts. Founded in 1998 as Amsterdam Molecular Therapeutics (AMT) Holding N.V., the company has evolved into a focused specialist in adeno-associated virus (AAV) gene therapy and commercial-grade manufacturing capabilities. Its history includes several important industry milestones, including the first approved gene therapy in the Western world and the successful U.S. IPO in 2014. ([uniqure.com](https://www.uniqure.com/pioneers-leaders/our-story)) For international investors, uniQure’s equity story is anchored in a concentrated pipeline aimed at severe genetic and neurological diseases. The company’s best-known asset is HEMGENIX® (etranacogene dezaparvovec), approved by the U.S. FDA for hemophilia B and later authorized in Europe, making it the world’s first gene therapy for hemophilia B. HEMGENIX validated uniQure’s AAV5 platform and demonstrated that the company can translate years of research into a commercially approved product. Beyond this franchise, uniQure is advancing AMT-130 for Huntington’s disease, which management has positioned as a lead clinical program and a potential disease-modifying therapy, alongside earlier-stage assets such as AMT-191 in Fabry disease, AMT-162 in SOD1 ALS, and AMT-260 in temporal lobe epilepsy. ([uniqure.com](https://www.uniqure.com/programs-pipeline/hemophilia?utm_source=openai)) Strategically, uniQure competes as a platform-based gene-therapy developer rather than a broad diversified pharmaceutical company. Its competitive edge rests on long-standing expertise in AAV biology, a track record of clinical and regulatory execution in ultra-rare diseases, and know-how in manufacturing and process development. That said, the company operates in one of the most challenging corners of biotech: the science is promising, but each program faces substantial clinical, regulatory, manufacturing, and financing risk. Its positioning is strongest in orphan and high-unmet-need indications where one-time or durable treatment paradigms can command meaningful medical and commercial interest. ([uniqure.com](https://www.uniqure.com/pioneers-leaders/our-story)) Recent developments have been strategically important. In July 2024, uniQure sold its Lexington, Massachusetts manufacturing facility to Genezen, a move designed to streamline operations and reduce cash burn while preserving access to manufacturing support. In February 2025, the company reported that its cash position, plus recent financing proceeds, was expected to fund operations into the second half of 2027, while also highlighting progress on AMT-130 and other pipeline programs. More recently, uniQure has continued to report clinical and regulatory progress across its pipeline, including updates for AMT-130 and AMT-191. Overall, the investment case remains that of a high-risk, high-upside gene-therapy platform company with meaningful scientific validation but substantial dependence on trial outcomes, FDA interactions, and capital discipline. ([uniqure.gcs-web.com](https://uniqure.gcs-web.com/static-files/c8264bc1-37f3-4d36-aec7-80910f23d58e))